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Aim To determine the general population willingness to 
pay for cognitive pharmacist service in community phar-
macy, describe the behavior of participants regarding 
health care issues, and evaluate correlation between par-
ticipants’ sociodemographic characteristics or attitudes 
and their willingness to pay.
Methods A questionnaire-based survey was conducted 
among general population visiting community pharma-
cies. The participants were asked about receiving cogni-
tive pharmacist services to identify and resolve potential 
medication therapy problems after the initiation of a new 
medicine to optimize health outcomes of the patients. A 
univariate and multivariate analysis were used to analyze 
associations between different variables and willingness to 
pay for pharmacy service.
Results Of 444 respondents, 167 (38%) reported that they 
were willing to pay for a medication management service 
provided in the community pharmacy. Univariate analysis 
showed significant association between the willingness 
to pay for pharmacist-provided service and respondents’ 
socio-demographic factors, health-related characteristics, 
and behavior, dilemmas, or need for certain pharmacist-
provided service. The logistic regression model was statisti-
cally significant (χ2 = 4.599, P < 0.001).
Conclusions The respondents expressed their willing-
ness to pay for cognitive pharmacist services, which has 
not been fully recognized within the health care system. In 
future, pharmacists should focus on practical implementa-
tion of the service and models of funding
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Pharmacists play a unique role in contributing to health 
outcomes of patients and improvement of patient’s qual-
ity of life due to accessibility of a pharmacy and pharmacist, 
traditional activity of supply and dispensing medicines, and 
pharmacy services related to the pharmacists’ use of spe-
cialized knowledge and abilities to help patients achieve 
effective and safe pharmacotherapy (1). Patient-oriented 
pharmacy services have been associated with the improve-
ment of clinical and economic outcomes, quality of life, pa-
tient safety, and reduction in morbidity and mortality (1-3).
Today, almost every health service or program needs to be 
evaluated in economic terms, justifying that the allocated 
money is worthwhile. Cost-benefit analysis is a type of eco-
nomic evaluation where both costs and outcomes of a cer-
tain health care program are expressed in monetary terms. 
One of the usually applied techniques to perform monetary 
valuation in cost-benefit analysis is willingness to pay, which 
can be assessed using the revealed or stated preferences 
approach, also known as contingent valuation. Contingent 
valuation uses survey methods to present participants with 
hypothetical scenarios about the health care program (4).
The same principles apply for the cognitive pharmacy 
services. Evaluation of the willingness to pay for different 
pharmacy services in developed countries showed that 
the general population was willing to pay for the cogni-
tive service provided in community pharmacies, where 
the amount was highly dependent on the service provid-
ed, but in certain cases reached more than US$30 (5-8). In 
less developed countries, willingness to pay for services in 
pharmacy was rarely evaluated, mainly because of the fo-
cus on traditional services, such as dispensing (5). Cogni-
tive pharmacy service, like medication therapy manage-
ment, differs from counselling during the dispensing of 
medicines because it includes comprehensive and overall 
review of patient’s medicines, dietary regime, and issues 
related to the medications usage (1).
The primary aim of this study was to determine general 
population’s willingness to pay for a cognitive pharmacist 
service in community pharmacies in Serbia. The secondary 
aims were to evaluate behavior of participants regarding 
the health care issues and explore the predictors of willing-
ness to pay and behavior.
PARTICIPANTS AND METHODS
A cross-sectional survey was conducted in community 
pharmacies in Serbia from April 25, 2016 to May 25, 2016.
Participants
Participants’ recruitment occurred at the counter when a 
customer approached the pharmacist. The pharmacist in-
vited customers to fill out a questionnaire at the counter. 
All customers entering the pharmacy were invited irre-
spective of their reason for visiting the pharmacy, posses-
sion of prescription, or specific service needed.
Participating pharmacies were selected to reflect the num-
ber and distribution of the pharmacies in Serbia. The sample 
of pharmacies was selected on the basis of a previous study 
investigating community pharmacy network in Serbia (6) 
and included 70 community pharmacies, either publicly or 
privately owned. Each pharmacy received 10 printed ques-
tionnaires to be distributed to the pharmacy customers.
Method
Pharmacy customers were asked to fill out the anonymous 
questionnaire inquiring about their demographic and 
health-related characteristics, behavior, the need for phar-
macy service, and willingness to pay for cognitive pharma-
cist service. The written explanation of the service included 
brief description of the possible counselling as follows: oral 
and written counselling and activities performed by the 
pharmacist to identify and resolve potential medication 
therapy problems after the initiation of a new medicine to 
optimize health outcomes of the patients, such as interac-
tions with current medications or diet, possible adverse ef-
fects, and what to expect from the treatment.
The participants’ willingness to pay was measured through 
close-ended binary choice question (yes/no). If the respon-
dents answered “yes” to the question about the willingness 
to pay, they were also asked to choose one of the defined 
values for the service. There were five defined values as 
follows: less than US$0.5, US$0.5-1, US$1-2.3, US$2.3-4.6, 
more than US$4.6. The values are linked with the Serbian 
health insurance system, where usual co-payment for the 
dispensed package of medicine is US$0.5. Serbia has so-
cial health insurance with compulsory funding through 
employers and employees contribution. The average gross 
salary in 2016 was US$567.9 (7), from which 10.3% deduc-
tion were allocated to health insurance. Participation in the 
survey implied the consent by the respondents.
Questionnaire
Dependent variable was willingness to pay for cognitive 
pharmacist service coded as “yes” or “no”, where ”no“ 
was considered as a reference category.
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The independent variables considered as potential pre-
dictors of willingness to pay for cognitive pharmacist pro-
vided service included socio-demographic characteristics, 
health-related characteristics and behavior, and dilem-
mas and need to certain pharmacist service. Socio-demo-
graphic characteristics included age (15-24, 25–34, 35-44, 
45-54, 55-64, and ≥65 years), gender (male/female), educa-
tion (primary, secondary, or graduate level), employment 
status (unemployed, employed, or retired), health care pro-
fessional (no/yes), and internet use (no/yes). Health-related 
characteristic and behavior of respondents included the 
frequency of pharmacy visiting (once a week, once in two 
weeks, once a month, or once in several months), number 
of pharmacies for medicine supply (1, 2-3, or >3), source of 
information on medicines (physician, pharmacist, friends 
and family, internet, or several of the above), presence 
of chronic disease (no/yes), and medication therapy for 
chronic disease (no/yes). Dilemmas and need for the cer-
tain pharmacist service included need for written informa-
tion from pharmacist (no/yes), dilemmas regarding the dis-
continuation of medication therapy due to adverse effect 
(no/yes), and dilemmas regarding the adequate medica-
tion administration and use (no/yes).
Statistical analysis
Descriptive statistical analysis including frequencies was 
used to present the study sample characteristics. A univariate 
analysis was used to analyze univariate associations between 
independent (potential explanatory) variables with willing-
ness to pay for pharmacy service. Crude odds ratio (cOR) 
with 95% confidence interval (CI) was used to explain the 
association of explanatory variable and willingness to pay. 
Variables found to be associated with medication use in the 
univariate analysis were included in the multivariate logistic 
regression model. The impact of variables on willingness to 
pay was estimated as adjusted odds ratio (aOR) with 95% CI. 
Hosmer-Lemeshow test of the goodness-of-fit was used to 
determine the goodness-of-fit of the model to the data.
Missing values were excluded from the analysis. The level 
of statistical significance was set at P < 0.05. Data analysis 
TAbLE 1. Socio-demographic characteristics of survey respondents
No. (%) of respondents*
Socio-demographic characteristic total (N = 444) willing to pay (n = 167) not willing to pay (n = 277)
Age group (years)
15-24  24 (5.4)   6 (1.4)  18 (4.1)
25-34 121 (27.4)  57 (12.9)  64 (14.5)
35-44  84 (19.0)  30 (6.8)  54 (12.2)
45-54  70 (15.9)  19 (4.3)  51 (11.6)
55-64  79 (19.7)  35 (7.9)  44 (9.8)
≥65  63 (14.3)  20 (4.5)  43 (9.8)
Gender
male 160 (37.1)  52 (12.1) 108 (25.1)
female 271 (62.9) 111 (25.8) 160 (37.1)
Education level
primary  23 (5.2)   5 (1.1)  18 (4.1)
secondary 210 (47.5)  66 (14.9) 144 (32.6)
graduate 209 (47.3)  95 (21.5) 114 (25.8)
Employment status
unemployed  82 (18.5)  27 (6.1)  55 (12.4)
employed 267 (60.3) 104 (23.5) 163 (36.8)
retiree  94 (21.2)  35 (7.9)  59 (3.3)
Healthcare professional
no 357 (81.5) 121 (27.6) 236 (53.9)
yes  81 (18.5)  42 (9.6)  39 (8.9)
Internet user
no 100 (23.1)  37 (8.5)  63 (14.5)
yes 333 (76.9) 125 (28.9) 208 (48.0
*Numbers do not add up due to missing values: age (3); gender (13); education (2); employment status (1); health care professional (6) and internet 
user (11).
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was performed using Statistical Package for Social Science 
(SPSS) software (SPSS 18.0 for Windows, SPSS Inc., Chicago, 
IL, USA).
RESULTS
The total number of respondents who completed the 
questionnaire was 444 .(response rate 63.4%). The mean 
age of participants was 45.1 ± 16.1 years, with 37.1% of sur-
vey respondents being male. There was an almost equal 
number of respondents with secondary or graduate level 
education, and 18.5% of respondents had medical back-
ground (Table 1).
A chronic disease, such as hypertension, diabetes, pulmo-
nary disease, or osteoporosis, was present in 39.3% of re-
spondents. About a third (32.7%) of the respondents re-
ported visiting a pharmacy once a month. The primary 
reasons for visiting a certain pharmacy were location of the 
pharmacy (27.5%), price of the products (27.1%), pharma-
cist service (23.1%) or pharmacy staff (21.7%). Physician and 
pharmacist were the respondents’ primary and secondary 
sources of information on medicines or medical condi-
tions (38.1% and 25.7%, respectively). Almost one quarter 
(23.4%) of the respondents did not contact any medical 
personnel for health-related information (Table 2).
A total of 30.9% of respondents expressed the need for 
detailed written information by pharmacist regarding the 
adequate medication usage and application (Table 3). A 
higher percentage of participants expressed dilemmas re-
garding the discontinuation of the therapy due to the ad-
verse effect of medicine or adequate medications usage 
(48.0% and 46.3%, respectively).
The willingness to pay for a medication management ser-
vice provided in the community pharmacy was expressed 
by 167 (38%) respondents. Almost equal percentage of 
respondents indicated a value for service of up to US$1 
(31.1% of respondents willing to pay for service), between 
US$1 and US$2.3 (29.3%) or between US$2.3 and US$4.6 
(28.1%).
A multivariate logistic regression was performed to ascer-
tain the effects of variables significantly associated in uni-
variate analysis on the likelihood that participants were 
willing to pay for cognitive pharmacist provided service. 
The logistic regression model (χ2 = 4.599, P < 0.001) ex-
TAbLE 2. Health-related characteristics and behavior of respondents
No. (%) of respondents*
Health-related characteristic total (N = 444) willing to pay (n = 167) not willing to pay (n = 277)
Frequency of pharmacy visiting
once a week 111 (25.0)  54 (12.2)  57 (12.8)
once in two weeks 118 (26.6)  41 (9.2)  77 (17.3)
once a month 145 (32.7)  52 (11.7)  93 (20.9)
once in several months 70 (15.8)  20 (4.5)  50 (11.3)
Number of pharmacies visited on regular basis
1 163 (37.2)  60 (13.7) 103 (23.5)
2-3 217 (49.5)  83 (18.9) 134 (30.6)
>3  58 (13.2)  20 (12.3)  38 (8.7)
Source of information on medicines and medical conditions
physician 169 (38.1)  53 (11.9) 116 (26.1)
pharmacist 114 (25.7)  56 (12.6)  58 (13.1)
friends and/or family 49 (11.0)  16 (3.6)  33 (7.4)
internet  55 (12.4)  19 (4.3)  36 (8.1)
several of above  57 (12.8)  23 (5.2)  34 (7.7)
Chronic disease
no 269 (60.7) 109 (24.6) 160 (36.1)
yes 174 (39.3)  57 (12.9) 117 (26.4)
Medication therapy for chronic diseases
no 275 (62.4) 108 (24.5) 167 (37.9)
yes 166 (37.6)  57 (12.9) 109 (24.7)
*Numbers do not add up due to missing values; number of pharmacies visited (6); chronic disease (1); medication therapy for chronic disease (3).
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plained 17.3% (Nagelkerke R2) of the variance and correctly 
classified 70.0% of cases. Hosmer-Lemeshow test P-value 
was >0.05.
Respondents with undergraduate level of education were 
5.95 times more likely to pay for cognitive pharmacist pro-
vided service than participants with primary level educa-
tion. Those who had medical background were 1.84 times 
more likely to pay than those without medical background. 
Additionally, using a pharmacist as the main source of 
medical information was associated with an increased like-
lihood of willingness to pay for cognitive pharmacist pro-
vided service, as well as the need for written information 
from pharmacist and the need for additional information 
about drug administration and use. The frequency of phar-
macy visits and need for medication therapy discontinua-
tion due to adverse effect were revealed as confounders in 
the multivariate analysis (Table 4).
DISCUSSION
We found that more than a third of the respondents were 
willing to pay for a pharmacy service aimed at optimizing 
therapeutic outcomes for a specific patient after the initia-
tion of the new medicine.
Pharmacist counselling was shown to have positive effect 
on patients’ drug and therapy knowledge, therapy adher-
ence, quality of life, reduction of medication-related prob-
lems, and demonstrate positive economic outcomes (8,9). 
Previous studies showed that between 13% and 57% of 
patients were willing to pay for a pharmacy service, de-
pending on the type of the provided service (10). A re-
cent study showed that 32.1% of patients were willing to 
TAbLE 3. Respondents’ dilemmas and need for the certain pharmacist service
No. (%) of respondents*
Dilemmas and needs total (N = 444) willing to pay (n = 167) not willing to pay (n = 277)
Need for written information from pharmacist
no 307 (69.1) 96 (21.6) 211 (47.5)
yes 137 (30.9) 71 (16.0)  66 (14.9)
Dilemmas regarding the discontinuation of 
medication therapy due to adverse effects
no 231 (52.0) 71 (16.0) 160 (36.0)
yes 213 (48.0) 96 (21.6) 117 (26.4)
Dilemmas regarding the adequate medication 
administration and use
no 237 (53.7) 69 (15.6) 168 (38.1)
yes 204 (46.3) 96 (21.8) 108 (24.5)
Note: Numbers do not add up due to missing values; dilemmas regarding the adequate medication administration and use (3).
TAbLE 4. Relationship between respondents’ characteristics 
and their willingness to pay for pharmacy service*
Variable aOR (95% CI)
Education
primary school reference
secondary school 3.33 (0.91-12.18)




Frequency of pharmacy visiting
once a week 1.84 (0.89-3.78)
once a two weeks 1.05 (0.52-2.13)
once a month 1.15 (0.59-2.24)
once a several months reference
Source of data about medicines
physician reference
pharmacist 1.89 (1.10-3.24)†
friends and/or family 1.39 (0.66-2.93)
internet 1.01 (0.50-2.03)
several of above 1.12 (0.55-2.22)
Need for written information from pharmacist
no reference
yes 1.86 (1.15-3.01)†
Need for medication therapy discontinuation 
due to adverse effect
no reference
yes 1.39 (0.88-2.20)




*All variables showing univariate association with the outcome 
entered the model and were retained regardless of their multivariate 
(independent) association with the outcome. Hosmer-Lemeshow test 
P > 0.05. aOR - adjusted odds ratio, CI - confidence interval.
†P < 0.05
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pay one of the pharmacy services aimed at asthma, dys-
lipidemias, or diabetes (11). However, other studies pre-
sented much higher percentage of patients who were 
willing to pay for certain pharmacy services. For the phar-
macy service that reduces the risk of drug- related prob-
lems by 40% to 20%, 60% of responders were willing to 
pay (12). Another study showed that more than 85% of 
women were willing to pay at least US$20 for pharmacist-
provided consultations on menopause and hormone re-
placement therapy (13). Similar monetary value (30 AUD) 
was obtained in the Australian research regarding the dia-
betes therapy management service in community phar-
macies (14). For the medication therapy management ser-
vices, Medicare patients were willing to pay US$33 (15). 
For the same service, patients in Canada were willing to 
pay lower amount (16). On the other hand, for less com-
plex pharmacy services, such as dispensing, patients were 
willing to pay much smaller amounts of money (5). Less 
complex services were not included in our study because 
they are part of usual pharmacist activity in community 
pharmacy.
In our study, the willingness to pay for pharmacy service 
closely correlated with higher respondents’ education, re-
spondent’s medical background, pharmacist being the 
main source of the information on medicines, and respon-
dent’s need for the service. Respondent’s age did not cor-
relate with the willingness to pay for cognitive pharmacist 
service, which is in line with previous findings (12-14,17,18). 
Similarly, the gender of the responders had no influence 
on the willingness to pay, as shown previously (12-14,17). 
Our findings on responders’ attitudes and the main source 
of medical information were comparable to the results 
from the 2001 National American Pharmacy Consumer 
Survey (18). Convenience was the primary motive for visit-
ing a specific pharmacy, followed by the product price and 
pharmacist service and participants ranked physicians and 
pharmacists as the first and second most important source 
of health-related information.
One of the rare studies that evaluated consumer rationale 
for not purchasing medication therapy management ser-
vice showed that the lack of financial resources was the 
most common reason (11). More than one-third of the 
respondents in our study expressed financial concerns, 
followed by the perception that the service was already 
provided by other health care professional or that these 
services were not needed. Financial concerns were most 
common in asthma management service, while the most 
common reason for dyslipidemia management service 
were the respondent’s perception that the service was al-
ready provided by other health care professionals.
In our study, the change in the respondents’ willingness to 
pay closely correlated with the percentage of out-of-pock-
et payment. Findings from the study by Schuh and Droege 
(19) suggested that less than half of patients were willing 
to pay 100% out-of-pocket for cognitive pharmacist ser-
vice. However, in case of the co-payment with the health 
insurance, the percentages of patients willing to pay were 
much higher, reaching 70.2% in case of 20% co-payment, 
or 84.7% if insurance completely covered the service. In 
our study, 38% of respondents reported willingness to pay 
for service provided in the community pharmacy, which 
may be explained by lower average salary in Serbia com-
pared with the more developed countries.
Currently, in most countries, payment for pharmacist ser-
vices is limited to the dispensing of the medicines or medi-
cal devices, with very little or none fee for the pharmacist 
cognitive service. In literature, there is a growing body of 
evidence on different models or mechanisms for sustain-
able financing and reimbursement of pharmacy services 
(20-22). The pharmacist contribution in improvement of 
health care, clinical, and humanistic outcomes of the pa-
tients has been well documented and primarily reflected 
in the knowledge, expertise, and accessibility of the phar-
macist as health care professional (21-24). In addition to 
the fact that patients recognize the pharmacist as medica-
tion expert, the importance of pharmacist cognitive servic-
es in the health promotion and disease prevention is not 
fully recognized by the patients. This can be explained by 
the insufficient patient knowledge, lack of awareness for 
the services provided, lack of separate counselling space in 
pharmacy, or lack of time (10,16,24,25). On the other hand, 
the physicians clearly appreciate the pharmacist contribu-
tion at primary health care level (10,21,26). Beside the phar-
macist’s contribution to patient’s clinical outcomes, phy-
sicians place much higher value on pharmacist service in 
monetary terms (26).
Wang and Hong (27) evaluated the pharmacists’ willing-
ness to accept a medication therapy management service 
and found that the pharmacist stated compensation level 
was significantly higher than compulsory compensation 
level or patients’ willingness to pay. Surprisingly, even in 
case of legislative opportunity for the compensation of 
the service (21), only 54% of pharmacist reported billing 
for provided service (28). The most common reason 
for not billing was “indigent population”, closely fol-
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lowed by “salaried position”, “company management does 
not support charging patients” and “lack of billing stan-
dardization”.
Although our respondents were willing to pay relative-
ly low monetary value for pharmacy service in Serbia, re-
sults should be carefully considered in the context of coun-
try economic development and the purchasing power of 
the general population. Also, our results may not be easily 
transferred and extrapolated on other pharmacy services or 
services provided in hospital setting. As a rule, much higher 
percentage of patients are willing to pay for pharmacy ser-
vices provided in hospitals with significantly higher level of 
compensation compared to services provided in commu-
nity pharmacy. The same applies to complex, comprehen-
sive pharmacist services. Even if the setting of the service 
was changed, eg, from hospital to treatment at home, pa-
tients would be willing to pay higher value for service (29).
The limitations of our study are typical. The willingness to 
pay studies determinate only the respondents’ claim that 
they would pay for the certain service or product, which 
does not necessarily imply that that would be the case in 
reality. This effect is named hypothetical bias. Studies cov-
ering this type of issues showed that application of the 
contingent valuation questionnaire resolves this issue (30-
32). Also, since the study was designed as cross-sectional, 
it was impossible to determine the causality.
In conclusion, our study showed the willingness of respon-
dents to pay for cognitive pharmacist service. Our results 
may provide additional supporting evidence to third par-
ty payers for the remuneration of those types of services. 
In order to obtain a wider perspective, the future research 
should focus on models of funding and practical imple-
mentation of the cognitive pharmacy service.
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